UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

1148 POSTER DAB2 Interactive Protein (DAB2IP) Methylation in Serum DNA of Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Mutations

European journal of cancer (1990), 2011, Vol.47, p.S138-S138

2011

Volltextzugriff (PDF)

Adenosquamous carcinoma, a rare and unknown tumor

Journal of oral medicine and oral surgery, 2018-10, Vol.24 (3), p.133-137

2018

Volltextzugriff (PDF)

Analysis of two consecutive series of unresectable high-grade glioma (HGG) patients (pts) treated with or without neoadjuvant chemotherapy before estandar radiochemotherapy (CRT) and adjuvant temozolamide (TMZ)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e12504-e12504

2012

Volltextzugriff (PDF)

Association of androgen receptor signature and RB1 , PTEN , TP53 gene expression with clinical outcome in metastatic hormone-sensitive prostate cancer treated with docetaxel and androgen deprivation therapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5069-5069

2021

Volltextzugriff (PDF)

Association of p53 mutations with progression-free survival (PFS) and overall survival (OS) in EGFR-mutated non-small cell lung cancer (NSCLC) patients (p) treated with erlotinib

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e18143-e18143

2012

Volltextzugriff (PDF)

Clinical and functional spectrum of RAC2-related immunodeficiency

Blood, 2024-04, Vol.143 (15), p.1476

2024

Volltextzugriff (PDF)

Development and validation of a gene expression signature based on RB1 , PTEN,and TP53 in patients with metastatic hormone-sensitive prostate cancer (mHSPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.236-236

2023

Volltextzugriff (PDF)

Differential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7540-7540

2012

Volltextzugriff (PDF)

The epidermal growth factor receptor (EGRF) in lung cancer

Translational respiratory medicine, 2015-02, Vol.3 (1), p.1-1, Article 1

2015

Volltextzugriff (PDF)

Estrogen receptor β and TMPRSS2-ERG expression association with clinical outcomes in metastatic hormone-sensitive prostate cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5077-5077

2022

Volltextzugriff (PDF)

First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature

Clinical & translational oncology, 2024-07

2024

Volltextzugriff (PDF)

Genome-scale phylogeny and comparative genomics of the fungal order Sordariales

Molecular phylogenetics and evolution, 2023-12, Vol.189, p.107938-107938, Article 107938

2023

Volltextzugriff (PDF)

Governance Foundations for the European Cybersecurity Community

Digital Sovereignty in Cyber Security: New Challenges in Future Vision, 2023, Vol.1807, p.132-148

2023

Volltextzugriff (PDF)

Interstitial Lung Disease Arising From Erlotinib Treatment in a Caucasian Patient

Clinical lung cancer, 2015-03, Vol.16 (2), p.e1-e3

2015

Volltextzugriff (PDF)

MCPH1 (BRIT1) and outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) harboring EGFR mutations

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e18131-e18131

2012

Volltextzugriff (PDF)

Metástasis auricular en carcinoma renal de células claras

Gaceta Mexicana de oncología, 2015-07, Vol.14 (4), p.222-224

2015

Volltextzugriff (PDF)

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting

Cancers, 2022-09, Vol.14 (18), p.4414

2022

Volltextzugriff (PDF)

National survey on patient's fears before a general surgery procedure

Cirugia Española, 2015-12, Vol.93 (10), p.643-650

2015

Volltextzugriff (PDF)

Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation

Journal of neuro-oncology, 2014-03, Vol.117 (1), p.77-84

2014

Volltextzugriff (PDF)

NOX2 deficiency enhances priming and activation of the NLRP3 inflammasome

Journal of allergy and clinical immunology, 2023-10

2023

Volltextzugriff (PDF)

PLCG2 associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants

Journal of allergy and clinical immunology, 2024-01, Vol.153 (1), p.230-242

2024

Volltextzugriff (PDF)

Polymorphisms in genes OPRM1, β-arrestin 2, STAT6, and COMT and clinical outcome to opioid therapy

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.9129-9129

2012

Volltextzugriff (PDF)

Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.5598-5598

2018

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(32)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Humans
(8)
Oncology
(8)
Patients
(4)
Male
(3)
Middle Aged
(3)
Adult
(2)
Aged
(2)
Allergy
(2)
Autoimmune Diseases
(2)
Biomarkers
(2)
Cancer Therapies
(2)
Care And Treatment
(2)
Chemotherapy
(2)
Docetaxel
(2)
Dosage And Administration
(2)
Female
(2)
Hematology, Oncology And Palliative Medicine
(2)
Immunologic Deficiency Syndromes - Genetics
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

1148 POSTER DAB2 Interactive Protein (DAB2IP) Methylation in Serum DNA of Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Mutations

Adenosquamous carcinoma, a rare and unknown tumor

Analysis of two consecutive series of unresectable high-grade glioma (HGG) patients (pts) treated with or without neoadjuvant chemotherapy before estandar radiochemotherapy (CRT) and adjuvant temozolamide (TMZ)

Association of androgen receptor signature and RB1 , PTEN , TP53 gene expression with clinical outcome in metastatic hormone-sensitive prostate cancer treated with docetaxel and androgen deprivation therapy

Association of p53 mutations with progression-free survival (PFS) and overall survival (OS) in EGFR-mutated non-small cell lung cancer (NSCLC) patients (p) treated with erlotinib

Clinical and functional spectrum of RAC2-related immunodeficiency

Development and independent validation of a predictive gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive metastatic prostate cancer (mHSPC)

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients

Development and validation of a gene expression signature based on RB1 , PTEN,and TP53 in patients with metastatic hormone-sensitive prostate cancer (mHSPC)

Differential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study

The epidermal growth factor receptor (EGRF) in lung cancer

Estrogen receptor β and TMPRSS2-ERG expression association with clinical outcomes in metastatic hormone-sensitive prostate cancer

First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature

Genome-scale phylogeny and comparative genomics of the fungal order Sordariales

Governance Foundations for the European Cybersecurity Community

Interstitial Lung Disease Arising From Erlotinib Treatment in a Caucasian Patient

MCPH1 (BRIT1) and outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) harboring EGFR mutations

Metástasis auricular en carcinoma renal de células claras

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting

National survey on patient's fears before a general surgery procedure

Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation

NOX2 deficiency enhances priming and activation of the NLRP3 inflammasome

PLCG2 associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants

Polymorphisms in genes OPRM1, β-arrestin 2, STAT6, and COMT and clinical outcome to opioid therapy

Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study)

Suchergebnisse filtern